ZA201008484B - Rasagiline for parkinson's disease modification - Google Patents

Rasagiline for parkinson's disease modification

Info

Publication number
ZA201008484B
ZA201008484B ZA2010/08484A ZA201008484A ZA201008484B ZA 201008484 B ZA201008484 B ZA 201008484B ZA 2010/08484 A ZA2010/08484 A ZA 2010/08484A ZA 201008484 A ZA201008484 A ZA 201008484A ZA 201008484 B ZA201008484 B ZA 201008484B
Authority
ZA
South Africa
Prior art keywords
rasagiline
parkinson
disease modification
disease
modification
Prior art date
Application number
ZA2010/08484A
Other languages
English (en)
Inventor
Ruth Levy
Eliav Eyal
Tamar Goren
Sheila Oren
Naim Sayag
Yonatan Weiss
Miri Ben-Ami
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of ZA201008484B publication Critical patent/ZA201008484B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA2010/08484A 2008-06-13 2010-11-25 Rasagiline for parkinson's disease modification ZA201008484B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13193608P 2008-06-13 2008-06-13
US18972408P 2008-08-22 2008-08-22
PCT/US2009/003528 WO2009151625A1 (en) 2008-06-13 2009-06-12 Rasagiline for parkinson's disease modification

Publications (1)

Publication Number Publication Date
ZA201008484B true ZA201008484B (en) 2012-05-30

Family

ID=41415378

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/08484A ZA201008484B (en) 2008-06-13 2010-11-25 Rasagiline for parkinson's disease modification

Country Status (13)

Country Link
US (2) US20090312436A1 (https=)
EP (2) EP2296462A4 (https=)
JP (3) JP2011522892A (https=)
CN (2) CN103893160A (https=)
AU (2) AU2009258151A1 (https=)
BR (1) BRPI0909894A2 (https=)
CA (1) CA2727022A1 (https=)
EA (1) EA201170018A1 (https=)
IL (1) IL209131A0 (https=)
MX (1) MX2010013766A (https=)
NZ (1) NZ589445A (https=)
WO (1) WO2009151625A1 (https=)
ZA (1) ZA201008484B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
US20090111892A1 (en) * 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
ES2551481T3 (es) * 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
JP5769923B2 (ja) * 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
CA2698695A1 (en) * 2007-09-05 2009-03-12 Teva Pharmaceutical Industries Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EP2234478A4 (en) * 2008-01-11 2013-01-23 Teva Pharma RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
US8334409B2 (en) * 2008-06-19 2012-12-18 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
BRPI0909997A2 (pt) 2008-06-19 2015-10-27 Teva Pharma r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
SI2451771T1 (sl) 2009-07-09 2014-10-30 Ratiopharm Gmbh Soli rasagilina in njihovi farmacevtski pripravki
EP2515891A4 (en) * 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
JP2013537530A (ja) * 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
SG189454A1 (en) * 2010-10-26 2013-05-31 Teva Pharma Deuterium enriched rasagiline
CA2732440C (en) * 2011-02-23 2017-10-31 Universite Laval Cystamine analogues for the treatment of parkinson`s disease
AU2012323346A1 (en) * 2011-10-10 2014-05-15 Teva Pharmaceutical Industries Ltd Rasagiline citramide
JP2014534197A (ja) 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド Ｒ（＋）−ｎ−メチル−プロパルギルアミノインダン
HK1200315A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤
US20150275302A1 (en) * 2014-04-01 2015-10-01 Teva Pharmaceutical Industries, Ltd. Determination of single nucleotide polymorphisms useful to predict response for rasagiline
EP3432931A1 (en) * 2016-03-26 2019-01-30 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositons for n-propargylamine derivative
CN110831606A (zh) * 2017-04-05 2020-02-21 克雷斯顿沃控股公司 治疗帕金森氏病(pd)和相关疾病的组合物和方法
EP3917508A4 (en) * 2019-01-28 2022-12-21 Mitochondria Emotion, Inc. EAAT2 ACTIVATORS AND METHODS OF USE THEREOF
GB202109826D0 (en) * 2021-07-07 2021-08-18 Bial Portela & Ca Sa Treatment regimens for early idiopathic parkinson's disease

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
CN1031995C (zh) * 1991-01-02 1996-06-12 奥韦特有限公司 N-炔丙基-1-氨基茚满的r-对映体的制法
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
ES2241064T3 (es) * 1996-12-18 2005-10-16 Teva Pharmaceutical Industries, Ltd. Derivados de aminoindano.
EP1418834A4 (en) * 2001-07-20 2007-04-04 Sinai School Medicine METHOD FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER DISEASE AND PARKINSON DISEASE
KR20060005009A (ko) * 2001-12-28 2006-01-16 다케다 야쿠힌 고교 가부시키가이샤 배뇨 장애 예방제/치료제
ES2432117T3 (es) * 2002-11-15 2013-11-29 Teva Pharmaceutical Industries Limited Uso de rasagilina con riluzol para tratar la esclerosis lateral amiotrófica
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
US20090111892A1 (en) * 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
WO2006091657A1 (en) * 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
CA2630037C (en) * 2005-11-17 2015-03-31 Teva Pharmaceutical Industries Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) * 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
ES2551481T3 (es) * 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
JP5769923B2 (ja) * 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
CN101600346B (zh) * 2006-12-14 2013-08-21 泰华制药工业有限公司 雷沙吉兰的单宁酸盐
CN101557706B (zh) 2006-12-14 2013-08-07 泰华制药工业有限公司 雷沙吉兰碱结晶固体
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090143388A1 (en) * 2007-08-29 2009-06-04 Mohanakumar Kochupurackal Para Treatment of brain disorders
CA2698695A1 (en) * 2007-09-05 2009-03-12 Teva Pharmaceutical Industries Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EP2234478A4 (en) * 2008-01-11 2013-01-23 Teva Pharma RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
BRPI0909997A2 (pt) * 2008-06-19 2015-10-27 Teva Pharma r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
US8334409B2 (en) * 2008-06-19 2012-12-18 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
DE102008064061A1 (de) * 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
AU2010304755A1 (en) * 2009-10-09 2012-05-24 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Progressive Supranuclear Palsy
EP2515891A4 (en) * 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan

Also Published As

Publication number Publication date
CA2727022A1 (en) 2009-12-17
WO2009151625A1 (en) 2009-12-17
EP2666356A1 (en) 2013-11-27
MX2010013766A (es) 2011-03-15
EP2296462A1 (en) 2011-03-23
AU2009258151A1 (en) 2009-12-17
BRPI0909894A2 (pt) 2015-07-28
US20140243418A1 (en) 2014-08-28
IL209131A0 (en) 2011-01-31
JP2015096532A (ja) 2015-05-21
EP2296462A4 (en) 2011-06-15
NZ589445A (en) 2013-06-28
CN102065687A (zh) 2011-05-18
JP2017081938A (ja) 2017-05-18
AU2016259315A1 (en) 2016-12-01
US20090312436A1 (en) 2009-12-17
JP2011522892A (ja) 2011-08-04
CN103893160A (zh) 2014-07-02
EA201170018A1 (ru) 2011-08-30

Similar Documents

Publication Publication Date Title
ZA201008484B (en) Rasagiline for parkinson's disease modification
IL205153A0 (en) Compositions for treating parkinson's disease
IL209896A0 (en) Compounds for treating symptoms associated with parkinson's disease
ZA201006127B (en) 4'4'-dioxaspiro-spirocyclically substituted tetramates
PL2985032T3 (pl) Glyx do stosowania do leczenia choroby alzheimera, choroby parkinsona lub choroby huntingtona
PL2197883T3 (pl) Pochodna katecholaminy użyteczna do leczenia choroby Parkinsona
WO2011044537A9 (en) Methods for treating alzheimer's disease
IL213120A0 (en) Method for treating parkinson' s disease
IL217149A0 (en) Compositions and methods for treating parkinson's disease
HK1156186A (en) Rasagiline for parkinson's disease modification
GB0822289D0 (en) "BABOO"babyseat carry
HK1175364A (en) Methods for treating parkinson's disease
GB0916264D0 (en) Diagnostic agent for parkinson's disease
AU2007905305A0 (en) Biomarkers for Parkinson's disease
HK1147194A (en) Compositions for treating parkinson's disease
GB0717956D0 (en) 20's
AU2008905035A0 (en) Alzheimer's disease biomarkers
GB0707985D0 (en) Easy's
IL206998A0 (en) Vaccine for alzheimer's disease
GB0821104D0 (en) Ivn 01
GB0808547D0 (en) Note 200007
GB0808548D0 (en) Note 200005
GB0808544D0 (en) Note 200010
GB0808553D0 (en) Note 200014
GB0808549D0 (en) Note 200004